Arbutus Biopharma's Clinical Trial Shows Promise for Hepatitis B Treatment
Arbutus Biopharma's Phase 2a trial shows 50% functional cure in HBeAg-negative patients with cHBV using imdusiran, IFN, and NA therapy, with 25% overall cure rate. No serious adverse events reported.
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the ...
New data from Phase 2a IM-PROVE II trial shows significant HBsAg declines in participants receiving imdusiran, VTP-300, and low-dose nivolumab, with 23% achieving HBsAg loss by Week 48.
© Copyright 2024. All Rights Reserved by MedPath